IVERIC bio Balance Sheet Health

Financial Health criteria checks 5/6

IVERIC bio has a total shareholder equity of $477.0M and total debt of $97.0M, which brings its debt-to-equity ratio to 20.3%. Its total assets and total liabilities are $613.4M and $136.4M respectively.

Key information

20.3%

Debt to equity ratio

US$96.99m

Debt

Interest coverage ration/a
CashUS$599.92m
EquityUS$477.05m
Total liabilitiesUS$136.36m
Total assetsUS$613.41m

Recent financial health updates

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Nov 03
IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Sep 28
Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Sep 16

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12
We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27
We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

IVERIC bio EPS misses by $0.05

Nov 02

Financial Position Analysis

Short Term Liabilities: ISEE's short term assets ($611.5M) exceed its short term liabilities ($39.4M).

Long Term Liabilities: ISEE's short term assets ($611.5M) exceed its long term liabilities ($97.0M).


Debt to Equity History and Analysis

Debt Level: ISEE has more cash than its total debt.

Reducing Debt: ISEE's debt to equity ratio has reduced from 445.2% to 20.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISEE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ISEE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies